Literature DB >> 25062797

Successful treatment of histiocytic sarcoma with induction chemotherapy consisting of dose-escalated CHOP plus etoposide and upfront consolidation auto-transplantation.

Hideki Tsujimura1, Toshiko Miyaki, Shuhei Yamada, Takeaki Sugawara, Mikiko Ise, Shintaro Iwata, Tsukasa Yonemoto, Dai Ikebe, Makiko Itami, Kyoya Kumagai.   

Abstract

Histiocytic sarcoma (HS) is an extremely rare malignant neoplasm that often exhibits an aggressive clinical presentation. In this report, we describe the case of a 38-year-old female with advanced-stage HS who was found to have a subcutaneous tumor in the left calf and enlarged lymph nodes in the left inguinal and internal iliac regions. The subcutaneous tumor and inguinal nodes were resected operatively. Immunohistochemistry of the surgical specimens showed that the malignant cells stained positive for CD163, CD68, and related markers; a diagnosis of HS was established. Following the administration of induction chemotherapy consisting of dose-escalated CHOP plus etoposide, the remaining internal iliac tumors disappeared. At that point, high-dose chemotherapy with autologous stem cell transplantation was performed as consolidation treatment. The patient remains alive with no evidence of disease for 30 months post-treatment. This report provides valuable insight into the treatment of advanced HS.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25062797     DOI: 10.1007/s12185-014-1630-y

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  16 in total

Review 1.  A case of resistant pediatric histiocytic sarcoma successfully treated with chemo-radiotherapy and autologous peripheral blood stem cell transplant.

Authors:  Chiara Mainardi; Emanuele S G D'Amore; Marta Pillon; Tiziana Toffolutti; Angelo Rosolen
Journal:  Leuk Lymphoma       Date:  2011-03-22

2.  Long-term remission after autologous stem-cell transplantation for relapsed histiocytic sarcoma.

Authors:  A Abu-Sanad; A Warsi; R P Michel; A Nahal; G Popradi; J M Storring; A S Liberman; T Alcindor
Journal:  Curr Oncol       Date:  2012-08       Impact factor: 3.677

Review 3.  Histiocytic sarcoma : an updated literature review based on the 2008 WHO classification.

Authors:  Emiko Takahashi; Shigeo Nakamura
Journal:  J Clin Exp Hematop       Date:  2013

4.  Successful treatment of refractory metastatic histiocytic sarcoma with alemtuzumab.

Authors:  Neerav Shukla; Rachel Kobos; Thomas Renaud; Julie Teruya-Feldstein; Anita Price; Linda McAllister-Lucas; Peter Steinherz
Journal:  Cancer       Date:  2011-12-13       Impact factor: 6.860

5.  Histiocytic sarcoma: a study of five cases including the histiocyte marker CD163.

Authors:  Jeffrey A Vos; Susan L Abbondanzo; Carol L Barekman; Joann W Andriko; Markku Miettinen; Nadine S Aguilera
Journal:  Mod Pathol       Date:  2005-05       Impact factor: 7.842

6.  Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases.

Authors:  S A Pileri; T M Grogan; N L Harris; P Banks; E Campo; J K C Chan; R D Favera; G Delsol; C De Wolf-Peeters; B Falini; R D Gascoyne; P Gaulard; K C Gatter; P G Isaacson; E S Jaffe; P Kluin; D M Knowles; D Y Mason; S Mori; H-K Müller-Hermelink; M A Piris; E Ralfkiaer; H Stein; I-J Su; R A Warnke; L M Weiss
Journal:  Histopathology       Date:  2002-07       Impact factor: 5.087

7.  Therapeutic outcome of multifocal Langerhans cell histiocytosis in adults treated with the Special C regimen formulated by the Japan LCH Study Group.

Authors:  Akira Morimoto; Chihiro Shimazaki; Satoshi Takahashi; Kouhei Yoshikawa; Ryosei Nishimura; Hisashi Wakita; Yutaka Kobayashi; Hirokazu Kanegane; Arinobu Tojo; Toshihiko Imamura; Shinsaku Imashuku
Journal:  Int J Hematol       Date:  2012-12-16       Impact factor: 2.490

Review 8.  PET/CT in malignant lymphoma: basic information, clinical application, and proposal.

Authors:  Ukihide Tateishi
Journal:  Int J Hematol       Date:  2013-09-25       Impact factor: 2.490

9.  Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant.

Authors:  Muneer H Abidi; Isaacson Tove; Rami B Ibrahim; Dan Maria; Edward Peres
Journal:  Am J Hematol       Date:  2007-10       Impact factor: 10.047

10.  Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL.

Authors:  Michael Pfreundschuh; Lorenz Trümper; Marita Kloess; Rudolf Schmits; Alfred C Feller; Christian Rudolph; Marcel Reiser; Dieter K Hossfeld; Bernd Metzner; Dirk Hasenclever; Norbert Schmitz; Bertram Glass; Christian Rübe; Markus Loeffler
Journal:  Blood       Date:  2004-02-24       Impact factor: 22.113

View more
  5 in total

1.  Response to MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma.

Authors:  Sophie Voruz; Anne Cairoli; Olaia Naveiras; Laurence de Leval; Edoardo Missiaglia; Krisztian Homicsko; Olivier Michielin; Sabine Blum
Journal:  Haematologica       Date:  2017-11-02       Impact factor: 9.941

2.  Increased tumor-infiltrating lymphocyte density is associated with favorable outcomes in a comparative study of canine histiocytic sarcoma.

Authors:  Jennifer A Lenz; Charles-Antoine Assenmacher; Victoria Costa; Katie Louka; Suzanne Rau; Nicholas S Keuler; Paul J Zhang; Robert G Maki; Amy C Durham; Enrico Radaelli; Matthew J Atherton
Journal:  Cancer Immunol Immunother       Date:  2021-08-20       Impact factor: 6.968

3.  Somatic mutations in histiocytic sarcoma identified by next generation sequencing.

Authors:  Qingqing Liu; Keith Tomaszewicz; Lloyd Hutchinson; Jason L Hornick; Bruce Woda; Hongbo Yu
Journal:  Virchows Arch       Date:  2016-06-03       Impact factor: 4.064

4.  Retroperitoneal Bulky Histiocytic Sarcoma Successfully Treated with Induction Chemotherapy Followed by Curative Surgery.

Authors:  Masafumi Oto; Akiko Maeda; Taku Nose; Yujiro Ueda; Shima Uneda; Akito Inadome; Koichi Oshima; Minoru Yoshida
Journal:  Intern Med       Date:  2017-09-15       Impact factor: 1.271

5.  Histiocytic Sarcoma Associated with Coombs Negative Acute Hemolytic Anemia: A Rare Presentation.

Authors:  Sandeep Batra; Stephen C Martin; Mehdi Nassiri; Amna Qureshi; Troy A Markel
Journal:  Case Rep Oncol Med       Date:  2016-06-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.